In Q2 2026, the biopharma industry didn't experience a disruption · it experienced a reclassification. AI drug discovery stopped being a venture bet and became an infrastructure investment. M&A surpassed a full year in six months. And a tariff structure created a permanent divide between organizations that moved and those that didn't.